Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 76, Issue 1, 2007, Pages 111-118

  Pan, Chang Yu ^a   Sinnassamy, Patrick ^b   Chung, Kab Do ^c   Kim, Kwang Won ^d  

^a Chinese PLA Hospital   (China)

^b SANOFI   (France)

^c Sanofi Korea   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Glycemic control; Insulin glargine; NPH insulin; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN;

ACCIDENTAL INJURY; ADULT; AGED; ANGINA PECTORIS; ARTHRITIS; ARTICLE; ASIAN; BACKACHE; BONE DISEASE; BREAST TUMOR; CELLULITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFECT; ENTERITIS; ETHNICITY; EYE DISEASE; FEMALE; FRACTURE; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MYASTHENIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PNEUMONIA; POPULATION; RANDOMIZED CONTROLLED TRIAL; RETINA DISEASE; SAFETY; STATISTICAL SIGNIFICANCE; URINARY TRACT DISEASE;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 33846933287     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.08.012     Document Type: Article

References (22)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. IDF, Diabetes and obesity: urgent action needed, 2004.
3. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (UK Prospective Diabetes Study Group). Lancet 352 (1998) 837-853
4. Peters A., and Davidson M. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann. Intern. Med. 115 (1991) 45-53
5. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
6. Riddle M. Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care 25 (2002) 395-396
7. Wright A., Burden A.C., Paisey R.B., Cull C.A., and Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
8. McCrimmon R.J., and Frier B.M. Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab 20 (1994) 503-512
9. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab. Res. Rev. 15 (1999) 42-46
10. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedalk M., and Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
11. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vincenzo A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
12. Owens D., Coates P., Luzio S., Tinbergen J., and Kurzhals R. Pharmacokinetics of [125]I-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 23 (2000) 813-819
13. 1c, fasting blood glucose (FBG) and hypoglycaemia using insulin glargine versus NPH insulin: a meta-regression analysis in Type 2 diabetes. Diabetes 52 (2003) A149 (abstract 642)
14. Yki-Jarvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23 (2000) 1130-1136
15. Riddle M., Rosenstock J., Gerich J., and I.G.S. Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
16. Fritsche A., Schweitzer M., Haring H.-U., and 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138 (2003) 952-959
17. WHO. Western Pacific Region IASO and IOTF: The Asia-Pacific Perspective: Redefining Obesity and its Treatment (2000), Health Communications Australia Pty Ltd., Sydney, Australia
18. ADA. Position statement: standards of medical care in diabetes-2006. Diabetes Care 29 Suppl. 1 (2006) S4-S42
19. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., Vahatalo M., Virtamo H., Nikkila K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
20. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
21. Fritsche A., Schweitzer M.A., and Haring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138 (2003) 952-959
22. Standl E., Maxeiner S., Raptis S., Karimi-Anderesi Z., and Schweitzer M.A. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 28 (2005) 419-420